TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BONESUPPORT HOLDING AB ( (SE:BONEX) ) has shared an update.
BONESUPPORT announced a strategic shift in the regulatory process for its CERAMENT V product, aimed at treating bone infections, by moving from the 510(k) application to the De Novo process with the U.S. FDA. This move is expected to establish a new product category, similar to the company’s previous success with CERAMENT G, potentially strengthening BONESUPPORT’s market position by making CERAMENT V the sole product in its category, despite the longer review period.
The most recent analyst rating on (SE:BONEX) stock is a Hold with a SEK210.00 price target. To see the full list of analyst forecasts on BONESUPPORT HOLDING AB stock, see the SE:BONEX Stock Forecast page.
More about BONESUPPORT HOLDING AB
BONESUPPORT is a leading company in orthobiology, specializing in the development and commercialization of innovative injectable bio-ceramic bone graft substitutes. These products, which can elute drugs and remodel to the patient’s own bone, are based on a patented technology platform. The company is headquartered in Lund, Sweden, and reported net sales of SEK 899 million in 2024.
Average Trading Volume: 245,180
Technical Sentiment Signal: Hold
Current Market Cap: SEK13.29B
For a thorough assessment of BONEX stock, go to TipRanks’ Stock Analysis page.